Eisenmenger Syndrome. A Clinical Perspective in a New Therapeutic Era of Pulmonary Arterial Hypertension

Journal of the American College of Cardiology

Volumn 53, Issue 9, 2009, Pages 733-740

  Beghetti, Maurice ^a   Galiè, Nazzareno ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Eisenmenger syndrome; physiopathology; pulmonary arterial hypertension; therapy

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN;

CONGENITAL HEART DISEASE; EISENMENGER COMPLEX; EXERCISE; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HEMODYNAMICS; HUMAN; OXYGEN SATURATION; PATENT DUCTUS ARTERIOSUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

ANTIHYPERTENSIVE AGENTS; EISENMENGER COMPLEX; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY CIRCULATION; PURINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES; SULFONES; THIOPHENES;

EID: 60449104617     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.11.025     Document Type: Review

References (69)

1. Eisenmenger V. Die angeborenen Defecte der Kammerscheidewand des Herzens. Z Klin Med 32 (1897) 1-28
2. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 2 (1958) 701-709
3. Daliento L., Somerville J., Presbitero P., et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 19 (1998) 1845-1855
4. Diller G.P., and Gatzoulis M.A. Pulmonary vascular disease in adults with congenital heart disease. Circulation 115 (2007) 1039-1050
5. Vongpatanasin W., Brickner M.E., Hillis L.D., and Lange R.A. The Eisenmenger syndrome in adults. Ann Intern Med 128 (1998) 745-755
6. Kidd L., Driscoll D.J., Gersony W.M., et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 87 Suppl (1993) I38-I51
7. Humbert M., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 Suppl S (2004) 13S-24S
8. Humbert M., Sitbon O., and Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351 (2004) 1425-1436
9. Pietra G.G., Capron F., Stewart S., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43 Suppl S (2004) 25S-32S
10. Simonneau G., Galiè N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 Suppl S (2004) 5S-12S
11. Hopkins W.E., Ochoa L.L., Richardson G.W., and Trulock E.P. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15 (1996) 100-105
12. Sheehan R., Perloff J.K., Fishbein M.C., Gjertson D., and Aberle D.R. Pulmonary neovascularity: a distinctive radiographic finding in Eisenmenger syndrome. Circulation 112 (2005) 2778-2785
13. Satoh T., Yagi T., Kato S., et al. A 38-year-old man with pulmonary hypertension, who had undergone atrial septal closure 26 years previously. Keio J Med 52 (2003) 250-262
14. Deanfield J., Thaulow E., Warnes C., et al. Management of grown up congenital heart disease. Eur Heart J 24 (2003) 1035-1084
15. Broberg C.S., Ujita M., Prasad S., et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 50 (2007) 634-642
16. Galiè N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
17. Berman E.B., and Barst R.J. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis 45 (2002) 129-138
18. Waddell T.K., Bennett L., Kennedy R., Todd T.R., and Keshavjee S.H. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 21 (2002) 731-737
19. Stoica S.C., McNeil K.D., Perreas K., et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 72 (2001) 1887-1891
20. Adriaenssens T., Delcroix M., Van Deyk K., and Budts W. Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome. Eur Heart J 27 (2006) 1472-1477
21. Batista R.J., Santos J.L., Takeshita N., et al. Successful reversal of pulmonary hypertension in Eisenmenger complex. Arq Bras Cardiol 68 (1997) 279-280
22. Mocellin R., and Buhlmeyer K. Late banding operation in children with ventricular septal defect and pulmonary arterial hypertension. Eur J Cardiol 3 (1975) 205-211
23. Novick W.M., Sandoval N., Lazorhysynets V.V., et al. Flap valve double patch closure of ventricular septal defects in children with increased pulmonary vascular resistance. Ann Thoracic Surg 79 (2005) 21-28
24. Afrasiabi A., Samadi M., and Montazergaem H. Valved patch for ventricular septal defect with pulmonary arterial hypertension. Asian Cardiovasc Thorac Ann 14 (2006) 501-504
25. Galiè N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
26. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007) 1917-1928
27. Post M.C., Janssens S., Van de Werf F., and Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J 25 (2004) 1651-1656
28. Budts W., Van Pelt N., Gillyns H., Gewillig M., Van De Werf F., and Janssens S. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart 86 (2001) 553-558
29. Christensen D.D., McConnell M.E., Book W.M., and Mahle W.T. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 94 (2004) 261-263
30. Gatzoulis M.A., Rogers P., Li W., et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 98 (2005) 147-151
31. Schulze-Neick I., Gilbert N., Ewert R., et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 150 (2005) 716
32. Gatzoulis M.A., Beghetti M., Galiè N., et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 127 (2008) 27-32
33. Berger R., Beghetti M., Galiè N., et al. Subgroup analysis of patients with atrial septal vs. ventricular septal defects in the BREATHE-5 placebo-controlled study of pulmonary arterial hypertension associated with Eisenmenger's syndrome. J Am Coll Cardiol 49 Suppl A (2007) 254A-271A
34. D'Alto M., Vizza C.D., Romeo E., et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart 93 (2007) 621-625
35. Diller G.P., Dimopoulos K., Kaya M.G., et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 93 (2007) 974-976
36. Apostolopoulou S.C., Manginas A., Cokkinos D.V., and Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 93 (2007) 350-354
37. Benza R.L., Rayburn B.K., Tallaj J.A., et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest 129 (2006) 1009-1015
38. Van Loon R.L., Hoendermis E.S., Duffels M.G., et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?. Am Heart J 154 (2007) 776-782
39. Brun H., Thaulow E., Fredriksen P.M., and Holmstrom H. Treatment of patients with Eisenmenger's syndrome with Bosentan. Cardiol Young 17 (2007) 288-294
40. Rosenzweig E.B., Rowan C.A., Barker L., and Barst R.J. Sitaxsentan treatment in patients with Eisenmenger syndrome. (abstr). Circulation 116 Suppl (2007) II457
41. Chau E.M., Fan K.Y., and Chow W.H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 120 (2007) 301-305
42. Garg N., Sharma M.K., and Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol 120 (2007) 306-313
43. Okyay K., Cemri M., Boyac B., Yalcn R., and Cengel A. Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with Eisenmenger syndrome. Cardiol Rev 13 (2005) 312-314
44. Singh T.P., Rohit M., Grover A., Malhotra S., and Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151 (2006) 851.e1-851.e5
45. Lim Z.S., Salmon A.P., Vettukattil J.J., and Veldtman G.R. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. Int J Cardiol 118 (2007) 178-182
46. Mukhopadhyay S., Sharma M., Ramakrishnan S., et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 114 (2006) 1807-1810
47. Palazzini M., Manes A., Romanazzi S., et al. Effects of sildenafil treatment in patients with pulmonary hypertension associated with congenital cardiac shunts. (abstr). Eur Heart J 28 Suppl (2007) 308
48. Rosenzweig E.B., Kerstein D., and Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99 (1999) 1858-1865
49. Fernandes S.M., Newburger J.W., Lang P., et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 91 (2003) 632-635
50. Frost A.E., Quinones M.A., Zoghbi W.A., and Noon G.P. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 24 (2005) 501-503
51. Schwerzmann M., Zafar M., McLaughlin P.R., Chamberlain D.W., Webb G., and Granton J. Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy. Int J Cardiol 110 (2006) 104-107
52. Gildein H.P., Wildberg A., and Mocellin R. Comparative studies of hemodynamics under prostacyclin and nifedipine in patients with Eisenmenger syndrome. Z Kardiol 84 (1995) 55-63
53. Hallioglu O., Dilber E., and Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 92 (2003) 1007-1009
54. Limsuwan A., Pienvichit P., and Khowsathit P. Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 26 (2005) 787-791
55. Beghetti M., Doran A.K., Mallory G., et al. Inhaled iloprost in children with pulmonary arterial hypertension. (abstr). Cardiol Young 17 Suppl 1 (2007) 78
56. Jansa P., Ambroz D., Maresová J., et al. Long-term experience with treprostinil infusion treatment in patients with pulmonary arterial hypertension in the Czech Republic. Vnitr Lek 53 (2007) 333-337
57. Ivy D.D., Doran A.K., Smith K.J., et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51 (2008) 161-169
58. Ikawa S., Shimazaki Y., Nakano S., Kobayashi J., Matsuda H., and Kawashima Y. Pulmonary vascular resistance during exercise late after repair of large ventricular septal defects. Relation to age at the time of repair. Thorac Cardiovasc Surg 109 (1995) 1218-1224
59. Adatia I. Pathophysiology of postoperative pulmonary hypertension. In: Beghetti M. (Ed). Pulmonary Arterial Hypertension Related to Congenital Heart Disease (2006), Elsevier, Munich 82-94
60. Schermuly R.T., Yilmaz H., Ghofrani H.A., et al. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 172 (2005) 358-363
61. Schermuly R.T., Pullamsetti S.S., Kwapiszewska G., et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 115 (2007) 2331-2339
62. Dumitrascu R., Weissmann N., Ghofrani H.A., et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113 (2006) 286-295
63. Zhao Y.D., Courtman D.W., Ng D.S., et al. Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer. Am J Respir Cell Mol Biol 35 (2006) 182-189
64. McMurtry M.S., Archer S.L., Altieri D.C., et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115 (2005) 1479-1491
65. Ghofrani H.A., Seeger W., and Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353 (2005) 1412-1413
66. Petkov V., Mosgoeller W., Ziesche R., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 (2003) 1339-1346
67. Oechslin E., Kiowski W., Schindler R., Bernheim A., Julius B., and Brunner-La Rocca H.P. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 112 (2005) 1106-1112
68. Lunze K., Gilbert N., Mebus S., et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest 36 Suppl (2006) 32-38
69. Galiè N., Rubin L.J., Hoeper M.M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan: results of the EARLY study. Lancet 371 (2008) 2093-2100